Article
Engineering, Biomedical
Zerin Mahzabin Khan, Jennifer M. M. Munson, Timothy E. E. Long, Eli Vlaisavljevich, Scott S. Verbridge
Summary: This study aims to further develop a thiol-Michael addition injectable hydrogel to capture and attract infiltrative glioblastoma cells and therapy-resistant glioblastoma stem-like cells (GSCs) through CXCL12-mediated chemotaxis. The results demonstrate that CXCL12 released from the synthetic hydrogel can induce the migration of GBM cells and GSCs from the extracellular matrix and promote invasion into the hydrogel through amoeboid migration. This synthetic hydrogel shows promise as a method to attract and capture migratory GBM cells and GSCs responsive to CXCL12 chemotaxis.
ADVANCED HEALTHCARE MATERIALS
(2023)
Article
Clinical Neurology
I-Tsang Chiang, Yu-Chang Liu, Hua-Shan Liu, Ahmed Atef Ahmed Ali, Szu-Yi Chou, Tsung- Hsu, Fei-Ting Hsu
Summary: Our study found that regorafenib can enhance the efficacy of temozolomide against glioblastoma by inhibiting the CXCL12/CXCR4/ERK/NF-κB signaling pathway. Additionally, regorafenib can sensitize glioblastoma cells to temozolomide and reduce tumor size and prolong survival in animal models.
Article
Oncology
Hala Awada, Francois Paris, Claire Pecqueur
Summary: Cancer treatment for Glioblastoma (GBM) is challenging due to limited survival and high relapse rates. This study explores the potential of immunotherapy targeting in GBM treatment by investigating the immunomodulatory effects of radiotherapy (RT) on tumors. The findings suggest that RT can modify the tumor immunogenicity and highlight the therapeutic potential of immunotherapy in fighting GBM.
Article
Medicine, Research & Experimental
Chunzhi Zhang, Yuan Zhou, Ya Gao, Ze Zhu, Xianliang Zeng, Weizi Liang, Songwei Sun, Xiuli Chen, Hu Wang
Summary: Radiation therapy increases the release of exosomes that promote the growth of irradiated glioblastoma cells by inducing M2 polarization of microglia. A circRNA called circ_0012381, which enters microglia via exosomes, induces M2 polarization by sponging with miR-340-5p. The inhibition of exosome secretion can significantly inhibit the growth of irradiated glioblastoma cells.
JOURNAL OF TRANSLATIONAL MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Nasser K. Yaghi, Mark R. Gilbert
Summary: This review examines the challenges faced by immunotherapies in treating glioblastoma, explores current treatment options, and proposes future directions for GBM immunotherapy.
Article
Oncology
Zili Tang, Ivana Dokic, Maximilian Knoll, Federica Ciamarone, Christian Schwager, Carmen Klein, Gina Cebulla, Dirk C. Hoffmann, Julian Schlegel, Philipp Seidel, Christiane Rutenberg, Stephan Brons, Christel Herold-Mende, Wolfgang Wick, Juergen Debus, Dieter Lemke, Amir Abdollahi
Summary: This study reveals that invasive tumor cells in glioblastoma exhibit high radioresistance and are closely associated with patient prognosis. Transcriptome analysis identifies the gene expression profile of invasive cells and validates the involvement of key pathways. Inhibition of specific signaling pathways and the use of carbon ion therapy can enhance the sensitivity of invasive cells to radiation treatment.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2022)
Review
Biochemistry & Molecular Biology
Alen Roncevic, Nenad Koruga, Anamarija Soldo Koruga, Robert Roncevic, Tatjana Rotim, Tihana Simundic, Domagoj Kretic, Marija Peric, Tajana Turk, Damir Stimac
Summary: Glioblastoma (GBM) is a highly aggressive glial tumor in the central nervous system. Current standard treatments only offer a median survival of 15 months. Tissue samples obtained during surgery are crucial for GBM diagnosis, and there is significant room for improvement in the current treatment methods.
Article
Oncology
Emma Liljedahl, Elise Konradsson, Emma Gustafsson, Karolina Fornvik Jonsson, Jill K. Olofsson, Kurt Osther, Crister Ceberg, Henrietta Nittby Redebrandt
Summary: Radiotherapy combined with complement activating therapy can effectively prolong survival in subcutaneous tumor models, but has limited effects in intracranial tumor models.
Article
Oncology
Miranda M. Tallman, Abigail A. Zalenski, Ian Stabl, Morgan S. Schrock, Luke Kollin, Eliane de Jong, Kuntal De, Treg M. Grubb, Matthew K. Summers, Monica Venere
Summary: The goal of this study was to validate the therapeutic efficacy of a small molecule inhibitor, KIF11, in increasing the sensitivity of glioblastoma (GBM) cells to radiotherapy and improving overall survival in patients. The results showed that KIF11 inhibition could radiosensitize GBM cells and improve overall survival in preclinical mouse models of GBM. These findings offer a new therapeutic modality that can increase the efficacy of radiotherapy for GBM with the ultimate goal of improving patient outcomes.
Article
Oncology
Hanna Meister, Thomas Look, Patrick Roth, Steve Pascolo, Ugur Sahin, Sohyon Lee, Benjamin D. Hale, Berend Snijder, Luca Regli, Vidhya M. Ravi, Dieter Henrik Heiland, Charles L. Sentman, Michael Weller, Tobias Weiss
Summary: This study demonstrated the generation of mouse and human mRNA-based multifunctional T cells coexpressing a multitargeting CAR and proinflammatory cytokines IL12 and IFN alpha 2, which exhibited enhanced antiglioma activity in vitro and in vivo compared to T cells expressing the CAR or cytokines alone. The coexpression of IL12 and IFN alpha 2 in addition to the CAR promoted a proinflammatory tumor microenvironment and reduced T-cell exhaustion, providing a rationale for future clinical studies with mRNA-based multifunctional CAR T cells in treating malignant brain tumors.
CLINICAL CANCER RESEARCH
(2022)
Review
Biochemistry & Molecular Biology
Henry Ruiz-Garcia, Cristopher Ramirez-Loera, Timothy D. Malouff, Danushka S. Seneviratne, Joshua D. Palmer, Daniel M. Trifiletti
Summary: Nanomedicine plays a crucial role in the treatment of GBM, with nanoparticles showing promise as radiosensitizers for improved therapeutic outcomes. Researchers are actively exploring novel treatment strategies, such as combining preoperative radiation with nanoradiosensitizers.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Engineering, Biomedical
Chih-Sheng Chiang, I-Ju Shih, Pei-Wei Shueng, Min Kao, Li-Wen Zhang, Shuo-Fu Chen, Ming-Hong Chen, Tse-Ying Liu
Summary: TSER is a strategy for achieving precision cell-targeted radiotherapy using common linear accelerators, involving a combination of GoldenDisk, 5-ALA, low-intensity ultrasound, and low-dose radiation therapy. It exhibited synergized radiosensitization effects and showed enhanced therapeutic effect and survival in the treatment of an orthotropic GBM model with only 20% of the radiation dose.
ACTA BIOMATERIALIA
(2021)
Article
Multidisciplinary Sciences
Silvia Chiesa, Antonella Mangraviti, Maurizio Martini, Tonia Cenci, Ciro Mazzarella, Simona Gaudino, Serena Bracci, Antonella Martino, Giuseppe M. Della Pepa, Martina Offi, Marco Gessi, Rosellina Russo, Matia Martucci, Francesco Beghella Bartoli, Luigi M. Larocca, Liverana Lauretti, Alessandro Olivi, Roberto Pallini, Mario Balducci, Quintino Giorgio D'Alessandris
Summary: This study aimed to identify molecular predictive factors for response to regorafenib in recurrent IDH-wildtype glioblastoma patients and found that mutations in the MAPK pathway may predict poor response and shorter survival in patients treated with regorafenib.
SCIENTIFIC REPORTS
(2022)
Article
Chemistry, Multidisciplinary
Xiao Liu, Zhengcong Cao, Weizhong Wang, Cheng Zou, Yingwen Wang, Luxiang Pan, Bo Jia, Kuo Zhang, Wangqian Zhang, Weina Li, Qiang Hao, Yingqi Zhang, Wei Zhang, Xiaochang Xue, Wei Lin, Meng Li, Jintao Gu
Summary: This study identified glutathione synthetase (GSS) as a potential regulator of radioresistance in glioblastoma (GBM) through in vivo loss-of-function genome-wide CRISPR screening and transcriptome analyses. High GSS levels were associated with poor prognosis and relapse in glioma patients. The study also developed a gene editing delivery system that could target the blood-brain barrier (BBB) and tumor for potential therapeutic translation.
Review
Biochemistry & Molecular Biology
Alejandro Rodriguez-Camacho, Jose Guillermo Flores-Vazquez, Julia Moscardini-Martelli, Jorge Alejandro Torres-Rios, Alejandro Olmos-Guzman, Cindy Sharon Ortiz-Arce, Dharely Raquel Cid-Sanchez, Samuel Rosales Perez, Monsserrat Del Sagrario Macias-Gonzalez, Laura Crystell Hernandez-Sanchez, Juan Carlos Heredia-Gutierrez, Gabriel Alejandro Contreras-Palafox, Jose de Jesus Emilio Suarez-Campos, Miguel Angel Celis-Lopez, Guillermo Axayacalt Gutierrez-Aceves, Sergio Moreno-Jimenez
Summary: Glioblastoma is a lethal tumor with limited treatment options. Efforts are being made in various research areas to find new therapies that can improve patient survival and quality of life.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Philipp Aumueller, Andreas Rothfuss, Martin Polednik, Yasser Abo-Madyan, Michael Ehmann, Frank A. Giordano, Sven Clausen
Summary: This article introduces a treatment planning system (TPS) that combines multiple direction needle-path planning with inverse dose optimization algorithms for assisting low-dose rate brachytherapy. The experimental results show that the TPS can generate treatment plans with acceptable dose coverage in a reasonable amount of time, and the results are in good accordance with a commercial TPS.
ZEITSCHRIFT FUR MEDIZINISCHE PHYSIK
(2022)
Article
Oncology
Vivien N. Sommerlath, Daniel Buergy, Nima Etminan, Stefanie Brehmer, David Reuss, Gustavo R. Sarria, Marie-Christin Guiot, Daniel Hanggi, Frederik Wenz, Kevin Petrecca, Frank A. Giordano
Summary: This study conducted a matched-pair analysis and found that MGMT promoter methylation and GFAP expression are associated with long-term survival in glioblastoma patients. Further prospective clinical trials are needed to confirm these findings.
RADIATION ONCOLOGY
(2022)
Article
Oncology
Cas S. Dejonckheere, Alexander M. C. Boehner, David Koch, Leonard C. Schmeel, Ulrich Herrlinger, Hartmut Vatter, Matthias Schneider, Patrick Schuss, Frank A. Giordano, Muemtaz A. Koeksal
Summary: This study focused on prognostic factors in primary gliosarcoma patients, finding that patients with lower symptom burden at diagnosis had better survival. However, other factors such as MGMT promoter hypermethylation and adjuvant temozolomide therapy did not influence survival.
STRAHLENTHERAPIE UND ONKOLOGIE
(2022)
Article
Medicine, Research & Experimental
Thomas Zeyen, Anna-Laura Potthoff, Robert Nemeth, Dieter H. Heiland, Michael C. Burger, Joachim P. Steinbach, Peter Hau, Ghazaleh Tabatabai, Martin Glas, Uwe Schlegel, Oliver Grauer, Dietmar Krex, Oliver Schnell, Roland Goldbrunner, Michael Sabel, Niklas Thon, Daniel Delev, Hans Clusmann, Clemens Seidel, Erdem Gueresir, Matthias Schmid, Patrick Schuss, Frank A. Giordano, Alexander Radbruch, Albert Becker, Johannes Weller, Christina Schaub, Hartmut Vatter, Judith Schilling, Frank Winkler, Ulrich Herrlinger, Matthias Schneider
Summary: This study aims to evaluate the safety and efficacy of combined MFA/TMZ therapy in patients with recurrent MGMT-methylated glioblastoma. If successful, MFA may become the first clinically feasible targeted drug against TMs.
Article
Oncology
Christian Moehring, Aliki Timotheou, Adrianna Manczak, Farsaneh Sadeghlar, Taotao Zhou, Robert Mahn, Alexandra Bartels, Malte Monin, Marieta Toma, Georg Feldmann, Peter Brossart, Muemtaz Koeksal, Gustavo R. Sarria, Frank A. Giordano, Philipp Lingohr, Azin Jafari, Joerg C. Kalff, Christian P. Strassburg, Maria A. Gonzalez-Carmona
Summary: This study analyzed the real-life experience of elderly patients with advanced or metastatic GC or AEG treated with FLOT as first-line palliative chemotherapy. The ECOG performance status showed a stronger prognostic value than patient age in this cohort.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Muemtaz Koeksal, Maike van der Hoek, Davide Scafa, David Koch, Christina Leitzen, Leonard C. Schmeel, Georg Feldmann, Andreas Strauss, Sebastian Koob, Frank A. Giordano
Summary: In this study, the researchers investigated the effects of adjuvant radiotherapy on patients with extremity soft-tissue sarcomas and analyzed the side effects of radiotherapy as well as predictive factors for patient prognosis. The results showed that radiotherapy was beneficial for improving local control, especially for high-grade sarcomas. Although radiotherapy caused some side effects, the occurrence rate of severe long-term function-limiting adverse events was low.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Mumtaz Koeksal, Romy Streppel, Stefan Hauser, Alina Abramian, Christina Kaiser, Maria Gonzalez-Carmona, Georg Feldmann, Niklas Schaefer, Sebastian Koob, Mohammed Banat, Motaz Hamed, Frank A. Giordano, Leonard C. Schmeel
Summary: This study investigated whether the severity of early side effects after radiotherapy are associated with patient nationality and other sociodemographic and clinical characteristics. The results showed that non-German patients were more likely to have severe side effects, and side effect severity was also associated with tumor entity, concomitant therapy, body mass index, and age. These findings suggest a need to develop targeted preventive measures for foreign cancer patients and further research on predicting factors for radiotherapy side effects, including other sociodemographic characteristics, to better personalize therapy regimens.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
J. Weller, N. Schaefer, C. Schaub, T. Tzaridis, T. Zeyen, M. Schneider, A. L. Potthoff, F. A. Giordano, J. P. Steinbach, P. S. Zeiner, T. Kowalski, M. Sabel, P. Hau, D. Krex, O. Grauer, R. Goldbrunner, O. Schnell, G. Tabatabai, F. Ringel, F. Schmidt-Graf, S. Brehmer, J. C. Tonn, L. Bullinger, P. Vajkoczy, M. Glas, H. Vatter, U. Herrlinger, C. Seidel
Summary: In the CeTeG/NOA-09 randomized phase III trial, TMZ/CCNU combination therapy was found to be superior to TMZ in newly diagnosed MGMT methylated glioblastoma, with higher incidence of hematotoxicity. This study analyzed high-grade hematotoxicity and its prognostic relevance in the trial population.
JOURNAL OF NEURO-ONCOLOGY
(2023)
Article
Oncology
Cas S. Dejonckheere, Alexander M. C. Boehner, Eva Schmitz, Tobias A. W. Holderried, Leonard C. Schmeel, Peter Brossart, Frank A. Giordano, Mumtaz A. Koeksal
Summary: A retrospective analysis of 48 adult patients showed that a longer interval of >= 3 days between TBI completion and allo-HSCT was associated with improved overall survival and better peripheral blood kinetics after successful engraftment, suggesting the importance of timing in improving patient outcomes.
Article
Oncology
Douglas Guedes de Castro, Paulo Issamu Sanematsu Junior, Antonio Cassio Assis Pellizzon, Sergio Hideki Suzuki, Ricardo Cesar Fogaroli, Jose Eduardo Souza Dias Junior, Guilherme Rocha Melo Gondim, Daniel Alvarez Estrada, Maria Leticia Gobo Silva, Marcio Saquy Rassi, Michael Jenwei Chen, Richard Giacomelli, Henderson Ramos, Elson Santos Neto, Carolina Humeres Abrahao, Tharcisio Machado Coelho, Liao Shin Yu, Cassio de Queiroz Tannous, Vinicius Fernando Calsavara, Frank Anton Giordano, Jean Goncalves de Oliveira
Summary: Objective: To evaluate the effect of intraoperative radiotherapy (IORT) on local control (LC) and brain disease control (BDC) after resection of brain metastases (BM). Conclusion: IORT for completely resected BM is associated with a potential high local control and low risk of radiation necrosis (RN), warranting further studies.
JOURNAL OF NEURO-ONCOLOGY
(2023)
Article
Oncology
Lea Hoppen, Gustavo R. Sarria, Chung S. Kwok, Judit Boda-Heggemann, Daniel Buergy, Michael Ehmann, Frank A. Giordano, Jens Fleckenstein
Summary: This study evaluated the impact of daily online adaptive radiation therapy (ART) strategies on dose-volume metrics in patients with lung cancer. The results showed that ART can reduce lung doses while maintaining good target coverage or escalate target doses without increasing ipsilateral lung exposure. The clinical benefits of these strategies should be further evaluated in prospective clinical trials.
RADIATION ONCOLOGY
(2023)
Review
Oncology
Stefan Janssen, Rami A. El Shafie, Arne M. Ruder, Daniel Buergy, Davide Scafa, Frank A. Giordano, Nils H. Nicolay, Marco M. E. Vogel, Stephanie E. Combs, Fabian B. Fahlbusch, Dirk Rades, Lukas Kaesmann
Summary: This article reviews the existing scientific literature on mobile applications in the field of radiation oncology and evaluates the characteristics of commercially available apps across different platforms. A systematic review of the literature and searches in major app marketplaces were conducted. The findings show that there is a limited availability of radiation oncology apps for patients and healthcare professionals in common marketplaces, with most apps focusing on supporting healthcare professionals.
STRAHLENTHERAPIE UND ONKOLOGIE
(2023)
Article
Oncology
Julian P. Layer, Katharina Layer, Gustavo R. Sarria, Fred Roehner, Cas S. Dejonckheere, Lea L. Friker, Thomas Zeyen, David Koch, Davide Scafa, Christina Leitzen, Muemtaz Koeksal, Frederic Carsten Schmeel, Niklas Schaefer, Jennifer Landsberg, Michael Hoelzel, Ulrich Herrlinger, Matthias Schneider, Frank A. Giordano, Leonard Christopher Schmeel
Summary: This study evaluates the safety and outcome profile of five-fraction stereotactic radiotherapy (FSRT) for brain metastases (BM). It shows that FSRT is a feasible and efficient approach for both adjuvant and definitive treatment, with acceptable local control rates and comparable radiation necrosis rates.
Meeting Abstract
Oncology
V. Volkenborn, G. R. Sarria, J. A. Holz, M. Denz, C. Leitzen, F. A. Giordano, S. Garbe
STRAHLENTHERAPIE UND ONKOLOGIE
(2022)
Review
Oncology
Varun Venkataramani, Matthias Schneider, Frank Anton Giordano, Thomas Kuner, Wolfgang Wick, Ulrich Herrlinger, Frank Winkler
Summary: This article discusses the role of multicellular tumour networks in brain tumours, as well as their relevance to therapy resistance and potential applications in other cancer types. The article shows how these networks are formed and how they drive tumour growth and resistance to standard therapies. The article also raises questions about how to disconnect brain tumour networks to halt tumour growth and improve treatment effectiveness. It discusses emerging principles of tumour networks and their translational implications.
NATURE REVIEWS CANCER
(2022)
